ID   H/Rb-M
AC   CVCL_JE92
SY   H/RB-M; H/Rb-M-CL5
DR   cancercelllines; CVCL_JE92
DR   CCRID; 4201PAT-CCTCC00099
DR   Wikidata; Q54871902
RX   Patent=WO1992022640A1;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10707.
CC   Characteristics: Corrects the lack of expression of RB1 in the parent cell line which is due to an homozygous mutation p.Tyr325Ter (c.975T>A).
CC   Sequence variation: Mutation; HGNC; HGNC:6871; MAPK1; Simple; p.Arg79Lys (c.236G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:9884; RB1.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0126 ! 5637
SX   Male
AG   68Y
CA   Cancer cell line
DT   Created: 15-05-17; Last updated: 19-12-24; Version: 16
//
RX   Patent=WO1992022640A1;
RA   Takahashi, Rei
RA   Benedict, William F.
RT   "Rb transferred cells and method.";
RL   Patent number WO1992022640A1, 23-Dec-1992.
//